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DERMATOFIBROSARCOMA PROTUBERANS: SURGICAL EXCISION VERSUS 
MOHS SURGERY.  Connie Chung, Mariel Eliza, Sumaira Aasi, David Leffell, and 
Deepak Narayan.  Section of Plastic Surgery and Section of Dermatologic Surgery and 
Cutaneous Oncology, Department of Surgery and Department of Dermatology, Yale 
University, School of Medicine, New Haven, CT. 
The purpose of this project was to compare the recurrence rates of dermatofibrsarcoma 
protuberans (DFSP) treated with surgical excision (SE) and Mohs surgery (MS) at Yale.  
Patients were identified through the dermatopathology laboratory database and stratified 
by treatment.  The following information was collected: age at onset, sex, disease state 
(primary presentation versus recurrence), tumor site, preoperative tumor size, 
postoperative defect size, excisional margin, duration of follow-up, and recurrence after 
treatment.  Of the 30 patients, 14 were in the SE group, and 16 were in the MS group.  
There were no recurrences in the SE group, and there was 1 recurrence (6%) in the MS 
group, which occurred 37 months post-operatively. The average area of the tumors were 
12.1 cm2 ± 16.1 (SE) and 5.3 cm2 ± 5.9 (MS), and the mean excisional margins were 3.8 
cm ± 1.6 (SE) and 1.4 cm ± 0.5 (MS). The mean duration of follow-up in the SE group 
was 33 months ± 41 (range: 1-116 months), and the mean duration of follow-up in the 
MS group was 26 months ± 25 (range: 2 to 69 months.)  Although the MS group had a 
higher recurrence rate than the SE group, using the recurrence rates to make meaningful 
conclusions about the efficacy of the two treatment modalities is limited by the small n, 
lack of randomization to either procedure, and duration of follow-up.  Once these issues 
are addressed, recurrence rates must also be adjusted for patient and tumor characteristics, 
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 Dermatofibrosarcoma protuberans (DFSP) is a malignant soft tissue neoplasm 
initially described in 1890 by Taylor, who wrote of a cutaneous tumor that looked like a 
keloid and had the potential to recur. (1)  More than 30 years later in 1924, Darier and 
Ferrand further characterized this clinical entity and named it “progressive and recurrent 
dermatofibroma.” (2)   In the following year, Hoffmann coined the term 
“dermatofibrosarcoma protuberans.” (3)  Today, DFSP remains a distinct entity marked 
by a triad of characteristics: its rarity, its slow growth, and its infiltrative nature. 
 On the whole, malignant soft tissue tumors are relatively rarer than carcinomas 
and other tumors, so they account for only 0.8% to 1% of all cancers diagnosed each year. 
(4)  Therefore, it is very difficult to determine the frequency and incidence of DFSP, and 
there are only a few large series that report the experience of a single institution over a 
period of time.  The earliest attempt found in the literature was in 1948 by Pack and 
Tabah, who had 39 cases in 50,000 patients admitted to their mixed tumor service over 
29 years. (5)  They calculated a frequency of DFSP of less than 0.1% of all tumors and an 
incidence of about 2 cases of DFSP a year.  In 1967, McPeak, Cruz, and Nicastri added 
86 more patients to this same service, and they attributed the threefold increase in 
incidence to a rise in the total number of patients seen, as well as to improved recognition 
of the distinct features of DFSP. (6) 
 More recently in the eighties, Bendix-Hansen and his group had 16 cases in 261 
patients with soft tissue sarcomas over 16 years, and they calculated a frequency of DFSP 
of 7% of all soft tissue sarcomas and an incidence of 0.8 cases of DFSP per one million 
persons per year. (7)  Finally, Chang et al. had 60 cases of DFSP treated between 1968 
and 2001, compared to approximately 100 patients with any type of soft tissue sarcoma 
who were treated each year at their institution (University of Illinois-Chicago), and 
therefore, DFSP accounted for approximately 1.8% of all soft tissue sarcomas 
encountered. (8)     
 Although the appearance of DFSP varies with the stage of the disease, DFSP 
initially presents as a slightly raised sclerotic plaque-like mass or small nipple-like 
projection on the surface of previously healthy skin, area of repeated trauma, vaccination 
site, irradiated skin, or scar. (9)  While firmly fixed to the overlying skin, DFSP is not 
attached to the underlying deeper structures, but there may be multiple satellite nodules at 
the periphery of the main lesion as well. (10)  Pressure on the surface of the lesion causes 
blanching (6), and the tumor is usually skin-colored with a brown-yellow or red tinge. (11) 
(Figure 1)  Occasionally, this discoloration precedes the development of a definite 
tumefaction. (12)  Therefore, this type of presentation can be misinterpreted as a keloid. 
(13)  Additionally, DFSP has been compared clinically with a morphea-type of basal cell 
carcinoma and scleroderma. (4)  
DFSP lesions typically arise on the trunk of the body, and in a series of 853 
patients, the authors observed the following site distribution: trunk, 47%; lower extremity, 
20%; upper extremity, 18%; and head and neck, 14%. (4)  Moreover, DFSP is slightly 
more common in men than in women, and in a series of 264 patients, the authors  
 
Figure 1: An indurated plaque with firm, irregular nodules varying in color from flesh to reddish brown. 
 
observed a male-to-female ratio of approximately 3:2. (14)  Known to arise in patients of 
widely varying ages, DFSP has an age distribution in the literature that ranges from six to 
87 years of age, but the majority of patients present during early- to mid- adult life. (15)  
There are a few reports citing lesions that presented in children, and there are 5 reported 
cases of DFSP being present since birth. (1, 5, 16) 
  DFSP is characteristically slow growing, resulting in a long latency period and 
lesions that persist for years without symptoms. (10)  Therefore, in 3 earlier series, the 
majority of patients did not seek medical care for at least 3 years. (6, 12, 17)  However, in 
2 more current series, the delay was usually less than 3 years. (7, 18)  Eventually, DFSP 
enters a rapid growth phase, producing pain or tenderness that usually prompts patients to 
seek medical evaluation of the lesion. (10)  As the rapidly growing mass enlarges, the 
overlying skin stretches and thins, which can lead to ulcerations and bleeding, and the 
lesion becomes fixed to the deep subcutaneous structures and fascial planes. (10)  
Moreover, the satellite nodules at the periphery of the lesion coalesce into a larger mass 
to obtain its typical “protuberant” appearance. (10)  Although areas of extremely large 
and neglected tumors may infarct and undergo spontaneous involution, deeper areas will 
continue to grow and invade the surrounding tissue. (10)  However, despite the enormous 
size of some DFSP tumors, patients may appear well and without the signs of cachexia 
that are commonly associated with other advanced cancers. (4)    
 The size of DFSP lesions at presentation, then, varies widely.  In a series of 159 
patients treated between 1950 and 1998, the authors found that the majority of lesions 
were <5 cm in maximum diameter, but the lesion sizes had the following distribution: 
<5cm, 134 patients (84%); 5-10 cm, 21 patients (13%); and >10 cm, 4 patients (3%). (15)  
Of note, the authors found that the DFSP lesions were predominantly superficial; 121 
patients (77%) had superficial lesions and 36 patients (22%) had lesions that had invaded 
deeper structures.  The depth of invasion was not reported in the remaining 2 patients 
(1%). 
 Biopsies of DFSP reveal gray-white, rubbery, fibrous tissue that makes up a 
solitary, multinodular, protuberant mass, and it is important to note that the mass appears 
deceptively well–circumscribed, because DFSP is characterized by an infiltrative growth 
pattern, and multiple finger-like projections can extend microscopically beyond the 
visible margins. (10)  In 1962, Taylor and Helwig meticulously described the 
microscopic features of DFSP with a series of 115 cases, and histologically, the central 
cellular portion of DFSP appears as a uniform population of atypical spindle-shaped cells 
that show little pleomorphism or mitotic activity. (17)  They observed that these cells 
organize themselves radially around the vasculature in a distinct, but monotonous, 
storiform or cartwheel pattern.  (Figure 2)   
 
 
Figure 2: Cells radiate from a central hub of fibrous tissue forming a cartwheel or storiform pattern. 
 
During the initial period of slow growth, DFSP grows laterally along the 
interfascicular spaces of the reticular dermis, so at the leading edge of the tumor, 
attenuated malignant cells blend imperceptibly with dermal fibroblasts, making the 
interface between tumor and normal tissue difficult to distinguish. (10)  As the lesion 
progresses, the tumor cells infiltrate the subcutaneous fat in an intricate, asymmetrical 
pattern, resulting in a honeycomb pattern of entrapped fat cells. (10)  (Figure 3)  Vertical  
 
 
Figure 3: DFSP extension into the subcutaneous fat results in a lacy or honeycomb pattern. 
 
infiltration occurs during the period of rapid growth, resulting in ulceration as DFSP 
spreads from the epidermis along the fascial planes of skeletal muscle. (10)  However, 
there are several unusual histological variants (Table 1), and the differential contains 
more than 10 diagnostic considerations (Table 2). (11)  
Table 1: DFSP variants     Table 2: Differential Diagnosis for DFSP 
 
-Atropic DFSP      -Atypical fibroxanthoma 
(morphea-like plaques)     -Classic fibrosarcoma 
-DFSP with giant cell angiofibroma   -Fasciitis 
-Fibrosarcomatous DFSP     -Myxofibrosarcoma 
(sarcomatous areas)     -Myxoid luposarcoma 
-Myxoid DFSP      -Cellular fibrous histiocytoma 
-Palisaded DFSP      -CD34+ benign fibrous hystiocytoma 
(reminiscent of schwannoma)    -Dermal dendrocytic hamartoma 
-Pigmented DFSP     -Dermatomyofibroma 
(Bednar tumor)      -Desmoplastic melanoma 
-Sclerosing DFSP     -Neurofibroma 
(abundant sclerotic tissue)     -Plexiform fibrohistiocytic tumor 
 
 It is important to note that regional and distant metastasis are rare despite the 
aggressive local invasiveness of DFSP.  In the early literature, the true incidence of 
metastases is difficult to assess because of the inclusion of other spindle cell tumors. (10)  
However, a recent study that used stricter criteria found that the risk for development of 
metastatic disease is approximately 5%. (14)  In this series of 913 cases of DFSP, 11 
patients, or 1%, had regional lymph node metastasis, and 37 patients, or 4%, had distant 
metastasis.  Moreover, the overwhelming majority of reported metastases of DFSP follow 
multiple local recurrences, and of these metastases, approximately 75% are 
hematogenous spread to the lungs, with the remaining 25% being lymphatic spread to the 
regional lymph nodes. (4)  Rare metastases to the brain, bone, and heart have also been 
documented. (4)  Increased cellularity and mitotic activity are important factors in 
enhancing the metastatic potential of DFSP. (19) 
 Differentiation of DFSP, therefore, is aided by immunostaining with CD34 and 
Factor XIIIa.  CD34 is a 110-kD glycosylated transmembrane protein of unknown 
function that is raised against the human myeloid leukemia cell line KG1a. (20)  In 
addition to being identified on vascular endothelial cells, their derivative tumors, and 
dendritic interstitial cells within the gastrointestinal tract (21, 22), CD34 has also been 
identified in 10 to 30% of the dendritic interstitial cells in the reticular dermis, as well as 
in spindle cells in and around the eccrine glands, and perifollicular spindle cells in the 
midportion of the hair follicle. (23)  However, dendritic interstitial cells in the upper 
papillary dermis, which are cytologically similar to those found in the reticular dermis, 
are immunophenotypically distinct, so they are CD34 negative but factor XIIIa positive. 
(24)  Factor XIIIa is a tetrameric protein also known as fibrin-stabilizing factor and plays 
a key role in the coagulation system. (25)  While DFSP stains positively for CD34 and 
negatively for factor XIIIa, dermatofibromas, or benign fibrous histiocytomas, stain 
negatively for CD34 and positively for factor XIIIa. (26)  This distinction is particularly 
clinically relevant in terms of treatment. 
 Three other novel markers can also help distinguish DFSP lesions from 
dermatofibromas.  Dermatofibromas tend to stain positively for CD44, a membrane 
glycoprotein thought to be the cell surface receptor for hyaluronate, the major component 
of the extracellular matrix, while DFSPs tend to have absent or significantly reduced 
CD44 immunostaining. (27)  Another marker than can help distinguish between DFSP 
lesions and dermatofibromas is p75, a low-affinity nerve growth factor receptor. (28)  A 
wide variety of mesenchymal and epithelial tumors stain positively for p75, indicating 
that p75 expression is not specific to nerve sheath tumors, but in one study, DFSP lesions 
stained positively of p75 in 69 of 73 DFSP lesions, or 95% of the lesions, while 
dermatofibromas had negative immunostaining for p75. (28)  Finally, Apo D, which is a 
33kDa glycoprotein that acts as a component of the high density lipoprotein structure, 
demonstrated strong immunoreactivity in 9 of 10 typical DFSP lesions in a study, as well 
as in 5 of 6 DFSP variants, while immunostains were negative in 16 of 16 
dermatofibromas, as well as in 12 of 12 dermatofibroma variants. (29) 
 Although thought to arise from a dermal stem cell or an undifferentiated 
mesenchymal cell with fibroblastic, muscular, and neurologic features, the pathogenesis 
of DFSP is not fully understood. (30)  However, Japanese researchers in 2002 
demonstrated that chromosomal translocations or ring chromosomes occur in DFSP 
through a fusion of chromosome regions 17q22 and 22q13. (31)  These gene locations 
code the alpha chain of type I collagen (COL1A1) and the beta chain of platelet-derived 
growth factors (PDGFβ), and the same abnormality is found in giant cell fibromas. (32)  
As a result, there is deregulation of PDGFβ chain expression, because the ring 
chromosome expresses a COL1A1-PDGFβ fusion protein that binds to the PDGF 
receptor β protein tyrosine kinase, leading to constant activation and stimulation for 
growth of DFSP cells. (33, 34) 
 The extent of deep invasion of DFSP can be evaluated with magnetic resonance 
imaging (MRI), and Torreggiani et al. applied this technique in a series of patients with 
large recurrent DFSP lesions. (35)  In their study, 10 patients with DFSP underwent MRI, 
and conventional T1-weighted images revealed the DFSP lesion to be isointense 
compared with skeletal muscle in 5 of the patients, slightly hypointense in 3 of the 
patients, and hyperintense in the remaining 2 patients.  Of note, all of the DFSP lesions 
were hypointense compared with the subcutaneous fat.  However, when conventional T2-
weighted images were obtained in 6 of the patients, and fast spin-echo T2-weighted 
images were obtained in the remaining 4 patients, half of the patients had DFSP lesions 
that had a higher signal intensity than that of subcutaneous fat, and half of the patients 
had DFSP lesions that had a similar signal intensity than that of subcutaneous fat.  On the 
other hand, computed tomography (CT) is not indicated as an initial diagnostic modality 
for DFSP lesions, except in rare cases in which one suspects underlying bone 
involvement. (8)  Although DFSP rarely exhibits lymphatic or hematogenous 
dissemination, the occasional patient with advanced, recurrent, and/or intermediate grade 
DFSP lesions may have pulmonary metastases, and therefore, it is recommended that 
these patients receive a chest x-ray. (8) 
 Although the American Joint Committee on Cancer has not set forth a system 
specific for the staging of DFSP, it is currently staged in accordance with the American 
Musculoskeletal Tumor Society (MSTS) staging system, which takes into account tumor 
grade and compartmentalization.  MSTS Stage 1A DFSP tumors are low-grade lesions 
without extension beyond the subcutaneous compartment, and Stage 1B DFSP tumors are 
low-grade lesions with extracompartmental extension into the underlying fascia or 
muscle. (36, 37)  
 While it is clear that the optimal treatment for DFSP is resection, the literature 
remains unclear about the optimal mode of resection, and patients may be treated by wide 
surgical excision or Mohs micrographic surgery.  In both procedures, the characteristic 
finger-like extensions of DFSP that lie beneath clinically normal appearing skin makes 
complete removal difficult, and recurrence rates of DFSP for both wide local surgical 
excision and Mohs micrographic surgery vary widely from study to study.  
 In wide surgical excision, clinically evident tumor is excised with a rim of normal 
appearing tissue.  This additional margin is removed because the characteristic 
microscopic extensions of DFSP cannot be visualized or palpated by the surgeon.  
Therefore, specimens are subsequently evaluated by pathologists.  Standard frozen 
sections are usually cut vertically, as in slicing a loaf of bread, measuring approximately 
10 millimicrons (mu) in thickness, and representative vertical sections are examined in 
each of the 4 quadrants of the specimen (ie. 12, 3, 6, and 9 o’clock positions). (38)  If the 
viewed sections do not show tumor, the margins are called clear.  Although other 
unexamined slices may still contain tumor, it is impractical to examine all of the vertical 
sections of a specimen; for example, a 5mm long piece of tissue would necessitate the 
preparation and examination of 5000 individual specimens.  Ultimately, less than 1% of 
the interface between the specimen and the patient is actually examined histologically 
(39), so standard vertical step sectioning may miss microscopic DFSP.  However, tumor 
recurrence is not correlated with tumor size, but correlated instead with resection margins 
of the tumor. (40)  In a study of 48 patients with DFSP, the authors found a trend toward 
decreasing recurrence with increasing excision margins; while there was a 41% 
recurrence rate with margins less than 2 cm, there was a 24% recurrence rate with 
margins greater than or equal to 2 cm. (40)  Currently, 3 cm margins are recommended in 
a standard wide surgical excision. (38) 
 In Mohs micrographic surgery, the dermatologist is both surgeon and pathologist, 
and the procedure couples serial excision with microscopic examination to trace the 
tumor.  Frederic E. Mohs originated this technique while working as a cancer research 
assistant during medical school in the early 1930s, serendipitously observing preservation 
of the microscopic detail of the tissue while testing the irritant effect of an intratumoral 
injection of 20% zinc chloride. (41)  His observation that the tissue appeared as though it 
had been excised and immersed in a fixative solution gave birth to the idea of excising 
tumors under microscopic control.  
 Currently, excision of a layer of the tumor is followed by evaluation of horizontal 
frozen sections to determine deep tumor margins, allowing preservation of the maximal 
amount of normal tissue. (42)  The tissue layer is 1) divided into smaller specimens, 2) 
numbered consecutively, 3) inked to distinguish left and right skin edges, and 4) mapped 
to show the anatomic origin of each specimen.  Frozen sections measuring 6-10 microns 
in thickness are sliced from the bottom and sides of each specimen, stained, and 
examined under the microscope by the dermatologist.  Residual tumor is drawn on the 
previously drawn map of the tissue layer, and the another tissue layer is removed.  This 
cyclic process of excision, mapping, and microscopic examination is repeated until no 
residual tumor is found microscopically. (42)  (Figure 4)  Therefore, almost 100% of the 
tumor margins are examined histologically. (39) 
 
Figure 4: Mohs surgery is a cyclic process of excision, mapping, and microscopic examination. (39) 
 
Statement of Purpose 
 The aim of this project was to compare the recurrence rates of DFSP treated with 
surgical excision and Mohs surgery at Yale with the hypothesis that the recurrence rate of 
DFSP treated with surgical excision would be lower than the recurrence rate of DFSP 
treated with Mohs surgery.  
Methods 
 Thirty patients were identified at the request of Drs. Aasi and Narayan by the 
Yale dermatopathology laboratory database as those who had been treated at this 
institution for DFSP from 1990, when the database was created, to 2005.  Patients were 
divided into two treatments groups according to whether they had undergone surgical 
excision or Mohs surgery.  Hospital and clinic charts were obtained by this author, who 
collect the following information: age at onset, sex, disease state (primary presentation 
versus recurrence), tumor site, preoperative and postoperative tumor size, excisional 
margin, duration of follow-up, and recurrence after treatment.  Attempts were not made 
to contact patients when follow-up data was not available in their medical records. 
 The recurrence rate and average duration of follow-up were then calculated for 
each of the treatment groups by this author.  Although data on excisional margins were 
available in the surgical excision group, data on excisional margins for the Mohs surgery 
group was not similarly available.  Therefore, excisional margins were calculated in the 
following manner: the larger measurement of the preoperative tumor size was subtracted 
from the larger measurement of the postoperative defect size to obtain a total margin.  
This total margin was divided in half based on the assumption that the margin was 
applied circumferentially around the lesion to yield the actual margin.  The smaller 
measurement of the preoperative tumor size was also subtracted from the smaller 
measurement of the postoperative defect size and divided in half.  These two values were 
then averaged to arrive at the excisional margin for each patient.  
Results 
Patient characteristics  
Of the 30 patients, 14 were in the surgical excision group, and 16 were in the Mohs 
surgery group.  The age range in the surgical excision group was 10 to 84 years, and the 
mean age was 46 years ± 19. The age range in the Mohs surgery group was 11 to 46 years, 
and the mean age was 38 years ± 12.  The distribution of sex was similar in each group; 
71% , or 10 out of 14 patients, were female in the surgical excision group, and 69%, or 11 
out of 16 patients, were female in the Mohs surgery group.  While none of the 30 patients 
presented to Yale with local or distant metastasis, 3 patients presented with recurrent 
DFSP.  Of these 3 patients, 1 was in the surgical excision group, and 2 were in the Mohs 
surgery group. 
Tumor characteristics 
 In the surgical excision group, most of the DFSP lesions were on the trunk, and a 
fifth of them were on the head or neck.  More specifically, there were 4 patients with 
lesions on the chest, 4 on the abdomen, and 3 on the back, totaling 11 out of 14 patients 
(79%) with lesions on the trunk.  The remaining 3 out of 14 patients (21%) in the surgical 
excision group had lesions on the head or neck.  (Figure 5)  In the Mohs surgery group, 
approximately half of the DFSP lesions (56%) were on the trunk, and a quarter of the 
DFSP lesions were on the extremities.  The remaining lesions were on the head or neck 
(2 out of 16 patients) and the vulva (1 out of 16 patients).  More specifically, there were 4 
patients with DFSP lesions on the chest, 3 on the abdomen, and 2 on the back, totaling 9 
out of 16 patients with lesions on the trunk.  Of the 4 DFSP lesions on the extremities in 
the Mohs surgery group, there were 3 lesions on the lower extremities and 1 lesion on the 
upper extremity.  (Figure 6)  The average area of the tumor was larger in the surgical 
excision group at 12.1 cm2 ± 16.1; the average area of the tumor in the Mohs surgery 
group was 5.3 cm2 ± 5.9. 





















Figure 5: Distribution of tumor location   Figure 6: Distribution of tumor location  
in the surgical excision group, n=14.    in the Mohs surgery group, n=16. 
 
 
Surgical excision vs. Mohs surgery 
 Mohs surgery was performed on all 16 DFSP patients in the Mohs surgery group 
by 1 dermatologist in the Section of Dermatologic Surgery and Cutaneous Oncology in 
the Department of Dermatology at Yale.  However, the 14 surgical excisions were carried 
out by 3 surgeons in the Section of Plastic Surgery in the Department of Surgery at Yale, 
as well as by the dermatologist previously mentioned.  The three plastic surgeons 
operated on 3 patients, 3 patients, and 5 patients respectively, and the dermatologist 
performed the remaining 2 surgical excisions. 
 The initial mean excisional margin for the surgical excision group was 2.8 cm ± 
0.4.  However, 6 of the 14 patients in the surgical excision group had positive margins on 
the final pathology report from their initial surgery, and they underwent a second surgical 
excision by the same physician.  (This second excision occurred within an average of 23 
days ± 13.)  When the excisional margins from the revision surgery were added to the 
initial margins, the mean excisional margin for the surgical excision group became 3.8 
cm ± 1.6.  (The width of the additional margins were available in the operative notes.)  
The mean excisional margin for the Mohs surgery group, however, was smaller at 1.4 cm 
± 0.5, and no revision procedures were required.  The mean duration of follow-up in the 
surgical excision group was 33 months ± 41, and the range of follow-up was 1 to 116 
months.  One of the patients in this group did not return for follow-up after her surgery.  
The mean duration of follow-up was shorter in the Mohs surgery group at 26 months ± 25, 
and the range of follow-up was 2 to 69 months.  Interestingly, one of the patients in this 
group did not return for follow-up after her surgery as well. (Table 3) 
Table 3: Summary of treatment data 
 
  Surgical Excision Mohs Surgery 
Margins 
 
3.8 ± 1.6 cm 1.4 ± 0.5 cm 
Follow-up 33 ± 41 months 26 ± 25 months 
Recurrence 0/14, 0% 1/16, 6% 
 
 There was 1 recurrence in this series, and the patient was in the Mohs surgery 
group.  This patient initially presented to Yale with a recurrent tumor, and he developed 
the recurrence 37 months after his Mohs surgery.  The dermatologist removed the 
recurrent tumor with surgical excision.  Therefore, the recurrence rate for the Mohs 
surgery group was 6% (1/16), and the recurrence rate for the surgical excision group was 
0%.    
Discussion 
 Dermatofibrosarcoma protuberans (DFSP) is a malignant soft tissue neoplasm 
with three key characteristics: it is very rare, it is slow growing, and it grows by 
asymmetric infiltration into deeper tissues.  Although there is a consensus in the literature 
that tumor excision is the most effective treatment of DFSP, there is currently no 
consensus on which excisional technique is the most effective, because the microscopic 
finger-like projections of DFSP are difficult to eradicate completely in either wide 
surgical excision or Mohs micrographic surgery.  Recurrence rates vary widely for both 
procedures, and moreover, recommended resection margins vary widely for wide surgical 
excisions. 
 Since the first studies in 1951, the literature currently contains over 30 series in 
which DFSP was removed by surgical excision. (Table 4)  The average recurrence rate 
was 23% (range: 0% to 60%), and the total recurrence rate was 21% (334/1598).  Given 
the variable follow-up periods, which ranged from 1 month to 25 years when stated, as 
well as variable numbers of patients, which ranged from 7 to 218, the large range of 
recurrence rates is not surprising.  Resection margins also ranged from “conservative” to 
5 cm when they were defined, but the vast majority of studies used excisional margins 
greater than or equal to 2 cm.  However, tumor location can limit the width of margins in 
surgical excision; generous excisional margins are not practical for DFSP on the face or 
distal extremities. (38) 
Table 4: Local recurrence rates after surgical excision of DFSP 
 








Pack, Tabah (5) 1951 39 8 21 0.5-20 
Gentele (43) 1951 38 16 42 NS 
McGregor (44) 1961 7 0 0 1-6 
Taylor, Helwig (17) 1962 98 48 49 1-17 
Burkhardt, et al. (12) 1966 21 7 33 >5 
McPeak, et al. (6) 1967 82 8 10 3-15 
Longhin (45) 1967 44 14 32 1-11 
Tamoney (46) 1971 12 3 25 1-30 
Hadju (47) 1979 119 64 53 NS 
Bendix-Hansen, et al. (7) 1983 18 8 44 5-13 
Barnes, et al. (48) 1984 15 8 53 1-23 
Waldermann, Hagedorn (49) 1985 13 3 23 1-7 
Petoin, et al. (50) 1985 96 6 6 1-15 
Roses, et al. (40) 1986 48 16 33 >3 
Chattopadhyay, et al. (51) 1986 10 6 60 5-7 
Rutgers, et al. (14) 1992 19 8 42 2-28 
Brabant, et al. (52) 1993 14 0 0 1-5 
Mark, et al. (53) 1993 15 9 60 3-16 
Koh, et al. (54) 1995 19 5 26 >3 
Gloster, et al. (38) 1996 39 5 13 0.8-14 
Arnaud, et al. (55) 1997 107 2 2 NS 
Gayner, et a. (56) 1997 32 11 34 0.8-24 
Sondak, et al. (57) 1999 45 0 0 NS 
Lindner, et al. (37) 1999 35 20 37 1-12 
Stojadinovic, et al. (58) 2000 33 3 9 NS 
Bowne, et al. (15) 2000 159 34 21 NS 
D’Andrea, et al. (59) 2001 14 1 7 2-8 
Oliveira-Soares, et al. (60) 2001 13 2 15 0.16-17 
Vandeweyer, et al. (61) 2002 18 1 5.5 NS 
Khatri, et al. (9) 2003 24 0 0 NS 
Chang, et al. (8) 2004 60 10 17 1-25 
Dubay, et al. (62) 2004 40 0 0 NS 
Fiore, et al. (63) 2005 218 8 4 NS 
Behbahani (64) 2005 34 0 0 NS 
      
Totals  1598 334 21  
 The use of Mohs surgery in the treatment of DFSP was first described in 1978 by 
Mohs himself. (65)  The literature currently contains at least 27 reports in which DFSP 
was removed by Mohs surgery, but almost a third of these reports have only 1 or 2 
patients in them. (Table 5)  The average recurrence rate was 1.9% (range: 0% to 14%), 
and the total recurrence rate was 2.7% (9/337).  Therefore, recurrence rates for Mohs 
surgery are lower than recurrence rates for surgical excision.  However, patients with 
surgical excision had a longer follow-up period, so patients with Mohs surgery may have 
late recurrences.  Also, Mohs surgery has several drawbacks that limit its widespread use 
in the treatment of DFSP. (57)  The Mohs surgeon requires considerable training, as well 
as a specialized ancillary team, and the learning curve is steep. (57)  Moreover, the 
surgery itself is labor and time intensive, and since it is performed under local anesthesia, 
large or bulky tumors are difficult to remove. (57) 
Table 5: Local recurrence rates after Mohs surgery for DFSP 
 








Mohs (65) 1978 7 0 0 >60 
Mikhail, Lynn (66) 1978 2 0 0 >60 
Peters, et al. (67) 1982 1 0 0 42 
Hess, et al. (68) 1985 1 0 0 18 
Robinson (69) 1985 4 0 0 >60 
Hobbs, Ratz (70) 1988 1 0 0 25 
Hobbs, et al. (71) 1988 10 0 0 15-91 
Weber, et al. (72) 1988 1 0 0 6 
Rockley, et al. (73) 1989 1 0 0 18 
Goldberg, Maso (74) 1990 1 0 0 12 
Parker, Zitelli (75) 1995 20 0 0 3-105 
Dawes, Hanke (76) 1996 24 2 8 NS 
Gloster, et al. (38) 1996 15 1 7 5-96 
Barlow, et al. (77) 1996 2 0 0 24-35 
Kelley, et al. (78) 1996 21 3 14 >60 
Garcia, et al. (79) 1996 16 0 0 NS 
Ratner, et al. (80) 1997 58 1 2 3-170 
Haycox, et al. (81) 1997 10 0 0 NS 
Hafner, et al. (82) 1999 5 0 0 NS 
Huether, et al. (83) 2000 18 1 5.5 NS 
Ah-Weng, et al. (84) 2002 21 0 0 21-80 
Nouri, et al. (85) 2002 20 0 0 4-216 
Oliveira-Soares, et al. (60) 2002 7 1 14 NS 
Tom, et al. (86) 2003 9 0 0 19-74 
Wacker, et al. (87) 2004 22 0 0 NS 
DuBay, et al. (62) 2004 11 0 0 NS 
Snow, et al. (42) 2004 29 0 0 60-240 
      
Totals  337 9 2.7  
 
 In this study, there was no recurrence in the surgical excision group, and there 
was 1 recurrence in the Mohs surgery group, resulting in a 6% recurrence rate for Mohs 
surgery and supporting the hypothesis that the recurrence rate of DFSP treated with 
surgical excision would be lower than the recurrence rate of DFSP treated with Mohs 
surgery.  However, this conclusion must be considered in light of several key limitations 
to this study. 
 First, this study had a small n since DFSP is a very rare disease; there were 14 
patients in the surgical excision group and 16 patients in the Mohs surgery group.  
Therefore, 1 or 2 recurrences can completely change the results of the study.  Even 1 
recurrence in the surgical excision group would lead to a 7% recurrence rate, and the rate 
of recurrence in the surgical excision group would be higher than the rate of recurrence in 
the Mohs surgery group. 
 Second, all of the patients in the study were referred to the dermatologist or 
plastic surgeon by their primary care physicians, but they were not randomly assigned to 
the 2 treatment groups.  However, the patients were not assigned to the 2 treatment 
groups by any identifiable criteria either.  Therefore, one cannot completely compare 
treatment outcomes, such as the recurrence rate, to conclude that one treatment modality 
is more effective than the other is. 
 Third, even if all of the patients were randomly assigned to the 2 treatment groups, 
comparing recurrence rates to evaluate the efficacy of surgical excision and Mohs surgery 
also depends on the length of follow-up.  More specifically, only recurrence rates at the 
same time point can be meaningfully compared, and the latest time point at which 
recurrence rates can be compared is equal to the shortest duration of follow-up among all 
of the patients.  In this study, the shortest duration of follow-up was only 1 month, 
despite a mean duration of follow-up for all of the patients of 29 months, and there were 
no recurrences in both the surgical excision and Mohs surgery groups at 1 month.  
However, no other meaningful comparisons of recurrence rates can be made beyond this 
time frame. 
 Finally, comparing recurrence rates for surgical excision and Mohs surgery 
demands adjustment for key factors, such as patient and tumor characteristics, in a 
multivariate analysis, because increased age, histologic subtype, high mitotic index, 
cellularity, location on the head and neck, and recurrent lesions are associated with higher 
recurrence rates. (15, 53, 56, 88)  Most recurrences occur within 3 years of the primary 
excision, and recurrent tumors tend to recur. (6, 17, 40, 48, 53)  Investigators in Germany 
specifically measured the subclinical spread of DFSP and found that, on average, 
recurring tumors infiltrated twice as far beyond the clinically visible tumor margin (22.4 
mm) as primary tumors (10.0 mm). (89)  
 There are 2 ways to overcome these limitations in order to compare the outcomes 
of surgical excision and Mohs surgery in the treatment of DFSP.  To increase the size of 
the study, concurrent data could be pooled from other institutions, or this data could be 
added to previous series listed in Tables 4 and 5, to make meaningful statistical analysis 
possible.  Moreover, this study would benefit greatly from contacting patients lost to 
follow-up in order to compare recurrence rates of surgical excision and Mohs surgery 
beyond 1 month. 
 However, while tumor resection remains the mainstay of treatment of DFSP, 
radiation therapy (RT) has an adjuvant role.  Although data assessing the efficacy of RT 
alone in the treatment of macroscopic disease is currently limited, several studies have 
concluded that RT administered before either before of after surgery significantly reduces 
the risk of local recurrence in patients who have or who are likely to have close or 
positive margins when wide excision would result in cosmetic or functional loss. (90, 91, 
92, 93)  In the most recent study in this series, 1 of the 10 patients (10%) who received 
adjuvant RT after surgical resection developed a recurrence, and 9 of the 24 patients 
(37.5%) who received only surgical resection developed a recurrence. (94)  The 
appropriate dose fractionation schedules and treatment techniques are similar to those 
that are used for other soft tissue sarcomas. (95)  Moreover, after reviewing a series of 
studies evaluating the efficacy of RT, the authors conclude that despite the limited data, 
RT alone is reasonably likely to result in cure for the occasional patient with unresectable 
macroscopic disease. (96)  However, the slow growth rate of DFSP precludes the use of 
chemotherapy as an effective treatment modality, (10) but may be used in metastatic 
disease. (49) 
 Finally, an additional adjuvant treatment option may be molecularly targeted 
therapy against the fusion protein COL1A1-PDGFβ.  As discussed above, this molecule 
is found in DFSP tumors and stimulates tumor growth.  Although originally approved for 
the treatment of chronic myelogenic leukemia, imatinib/STI-571 (Gleevec), which is a 
potent and specific inhibitor of several protein-tyrosine kinases, also interrupts the 
continuous stimulation of the DFSP cells by inhibiting platelet-derived growth factor 
receptors in vitro (34, 97) and in selected patients. (98)  In 2003, the Task Force for 
Dermatologic Oncology (ADO), together with the German Society for Dermatologic 
Surgery and Oncology, initiated an open, multi-institutional phase II study to evaluate the 
therapeutic efficacy of Gleevec in a larger patient population. (11) 
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